COAG
Hemab Therapeutics Holdings, Inc.
Set alert
- YTD
- +21.91%
- 1 year
- +21.91%
- Open
- 40.34
- Prev close
- 40.42
- Mkt cap
- 1.94B
- Vol
- 765.62K
- Avg vol
- 454.15K
- EPS
- -4.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 39.38
- High
- 42.85
- Forward P/E
- -16.20
- Beta
- 0.00
- Short ratio
- 5.27
- Inst. own
- 92.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2026
- 50-d avg
- 38.04
- 200-d avg
- 36.74
- 1y target
- 62.67
News
-
2 weeks ago benzinga.com
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70
JP Morgan analyst Joyce Zhou initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Overweight rating and announces Price Target of $70.
-
2 weeks ago benzinga.com
Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $56.
3 weeks ago defenseworld.net
Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Here’s What Happened
Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) gapped down prior to trading on Thursday. The stock had previously closed at $32.60, but opened at $30.82. Hemab…
4 weeks ago defenseworld.net
Hemab Therapeutics (NASDAQ:COAG) Sees Strong Trading Volume – Should You Buy?
Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) saw strong trading volume on Wednesday. 332,235 shares were traded during trading, a decline of 11% from the previous session's…
4 weeks ago defenseworld.net
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of “Moderate Buy” from Analysts
Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, Marketbeat…
1 month ago globenewswire.com
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board Keli Walbert brings two decades of commercial leadership and proven track record…
1 month ago globenewswire.com
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care…
2 months ago benzinga.com
Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of Webuy Global Ltd (NASDAQ:WBUY) rose sharply in pre-market trading. Webuy reported record preliminary unaudited travel bookings of around $4.76 million during the three-day NATAS Fair in…
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64
Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60
HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $52 to $60.
-
2 months ago benzinga.com
Hemab Therapeutics Hldgs Q2 EPS $(0.80) Misses $(0.52) Estimate
Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.52) by 53.85 percent. This is a 93.8 percent increase over…
3 months ago defenseworld.net
Hemab Therapeutics (NASDAQ:COAG) Shares Up 5.5% – Should You Buy?
Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report)'s share price traded up 5.5% on Friday. The stock traded as high as $47.00 and last traded at $47.00. 17,722 shares traded hands…
3 months ago seekingalpha.com
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COAG's robust cash position post-IPO funds operations…
-
3 months ago benzinga.com
Hemab Therapeutics Presents Clinical, Preclinical Data From Sutacimig In Glanzmann Thrombasthenia And Factor VII Deficiency At International Society On Thrombosis And Haemostasis 2026 Congress
Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today…
3 months ago globenewswire.com
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026
-
3 months ago benzinga.com
Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47
Jefferies analyst Maury Raycroft maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $39 to $47.
3 months ago benzinga.com
Hemab Advances Bleeding Disorder Pipeline
Hemab Therapeutics Inc. (NASDAQ:COAG) on Sunday presented new clinical data for its lead candidate HMB-002 in Von Willebrand disease (VWD) and introduced HMB-003, a new program targeting heavy…
3 months ago benzinga.com
Hemab Advances Bleeding Disorder Pipeline
Hemab reports new HMB-002 Von Willebrand disease data, and introduced HMB-003, targeting heavy menstrual bleeding.
-
3 months ago benzinga.com
CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55
Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $42 to $55.
-
3 months ago benzinga.com
Wedbush Reiterates Outperform on Hemab Therapeutics Hldgs, Maintains $55 Price Target
Wedbush analyst David Nierengarten reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and maintains $55 price target.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $52
HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $40 to $52.
-
3 months ago benzinga.com
Reported Sunday, Hemab Therapeutics Presents New HMB-002 Clinical Data Showing ≥2.4-Fold Dose-Dependent VWF And FVIII Increases In Von Willebrand Disease, Introduces HMB-003 For Heavy Menstrual Bleeding At ISTH 2026 Congress
HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of…
3 months ago globenewswire.com
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Hemab Therapeutics Hldgs, Maintains $40 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and maintains $40 price target.
-
4 months ago benzinga.com
Hemab Therapeutics To Present Clinical And Preclinical Data From Multiple Blood Coagulation Programs At ISTH 2026 July 11-15
Presentation Highlights and Details – The abstracts are now available through the ISTH conference websiteSutacimigSutacimig showed sustained prophylaxis in GT (meaningful reduction in ATBR and…
4 months ago globenewswire.com
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous…
4 months ago benzinga.com
This Charles River Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Top Wall Street analysts upgraded MITT & MFA. See ratings & price targets for these stocks. Should you buy MFA?
4 months ago benzinga.com
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top analysts changed outlook on top names. See all changes, including upgrades/downgrades/coverage initiations at Benzinga's analyst ratings page.
-
4 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $40
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $40.
4 months ago marketbeat.com
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
Hemab Therapeutics NASDAQ: COAG Chief Executive Officer Benny Sorensen outlined the company's development plans following its recent initial public offering during a fireside chat with Jefferies…
5 months ago globenewswire.com
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment…
-
5 months ago benzinga.com
Wedbush Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $42
Wedbush analyst David Nierengarten initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $42.
-
5 months ago benzinga.com
Jefferies Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $39
Jefferies analyst Maury Raycroft initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $39.
-
5 months ago benzinga.com
Evercore ISI Group Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $50
Evercore ISI Group analyst Cory Kasimov initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $50.
5 months ago benzinga.com
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.
-
5 months ago benzinga.com
Goldman Sachs Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $36
Goldman Sachs analyst Richard Law initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $36.
-
5 months ago benzinga.com
Hemab Therapeutics Hldgs Q1 EPS $(23.98) Down From $(16.18) YoY
Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(23.98) per share. This is a 48.21 percent decrease over losses of $(16.18) per share from the same period last year.
5 months ago globenewswire.com
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine…
5 months ago benzinga.com
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
US stock futures lower, Dow futures down 200 points. Norwegian Cruise Line shares fall after Q1 results, cuts FY guidance. Other stocks also down.
5 months ago benzinga.com
Why eBay Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, valuing GME at $55.5B. eBay shares jumped 8.1% to $112.50 in pre-market trading.
6 months ago seekingalpha.com
U.S. IPO Weekly Recap: Biotech, Early-Stage Mining, And Bill Ackman Close Out The April IPO Market
Four IPOs priced this past week, led by three sizable biotechs. They were joined by 11 blank check listings. Two IPOs are currently scheduled for the week ahead, though some smaller names may join…
6 months ago globenewswire.com
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that…